Alexion Pharmaceuticals Files Form 10-Q for Third Quarter 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Alexion Pharma (ALXN) a High Conviction Idea at Citi as 10-Q Overhang Removed
January 5, 2017 9:04 AM ESTCiti analyst Robyn Karnauskas called Alexion Pharma (NASDAQ: ALXN) a 2017 high conviction 'Buy' idea after the 10-Q overhang was lifted with no restatement.
She expects: 1) no restatement & 2) maintaining 2016 guidance will be considered positive by the street.
"We see 2017 guidance... More

